Dublin, Feb. 04, 2020 (GLOBE NEWSWIRE) -- The "Amyotrophic Lateral Sclerosis (ALS) Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Amyotrophic Lateral Sclerosis (ALS) Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the amyotrophic lateral sclerosis (ALS) market. A detailed picture of the amyotrophic lateral sclerosis (ALS) pipeline landscape is provided, which includes the disease overview and amyotrophic lateral sclerosis (ALS) treatment guidelines.

The assessment part of the report embraces in-depth amyotrophic lateral sclerosis (ALS) commercial assessment and clinical assessment of the amyotrophic lateral sclerosis (ALS) pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, amyotrophic lateral sclerosis (ALS) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

• All of the companies that are developing therapies for the treatment of amyotrophic lateral sclerosis (ALS) with aggregate therapies developed by each company for the same.
• Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the amyotrophic lateral sclerosis (ALS) treatment.
• Amyotrophic lateral sclerosis (ALS) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of amyotrophic lateral sclerosis (ALS) market.

Scope of the Report

• The amyotrophic lateral sclerosis (ALS) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for amyotrophic lateral sclerosis (ALS) across the complete product development cycle, including all clinical and nonclinical stages.
• It comprises of detailed profiles of amyotrophic lateral sclerosis (ALS) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.
• detailed amyotrophic lateral sclerosis (ALS) research and development progress and trial details, results wherever available, are also included in the pipeline study.
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across amyotrophic lateral sclerosis (ALS).

Key Topics Covered

1. Report Introduction

2. Amyotrophic lateral sclerosis (ALS)
2.1. Overview
2.2. History
2.3. Amyotrophic lateral sclerosis (ALS) Symptoms
2.4. Causes
2.5. Pathophysiology
2.6. Amyotrophic lateral sclerosis (ALS) Diagnosis
2.6.1. Diagnostic Guidelines

3. Amyotrophic lateral sclerosis (ALS) Current Treatment Patterns
3.1. Amyotrophic lateral sclerosis (ALS) Treatment Guidelines

4. Amyotrophic lateral sclerosis (ALS) - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Amyotrophic lateral sclerosis (ALS) companies collaborations, Licensing, Acquisition - Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Amyotrophic lateral sclerosis (ALS) Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Amyotrophic lateral sclerosis (ALS) Acquisition Analysis

5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target

6. Amyotrophic lateral sclerosis (ALS) Late Stage Products (Phase-III)

7. Amyotrophic lateral sclerosis (ALS) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Amyotrophic lateral sclerosis (ALS) Discontinued Products

13. Amyotrophic lateral sclerosis (ALS) Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table

14. Amyotrophic lateral sclerosis (ALS) Key Companies

15. Amyotrophic lateral sclerosis (ALS) Key Products

16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation

17. Amyotrophic lateral sclerosis (ALS) Unmet Needs

18. Amyotrophic lateral sclerosis (ALS) Future Perspectives

19. Amyotrophic lateral sclerosis (ALS) Analyst Review

20. Appendix

21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ipzljk

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.